Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test may spot hidden heart failure in seniors

NCT ID NCT04699890

Diagnosis Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to create better diagnostic tools for a type of heart failure called heart failure with preserved ejection fraction (HFpEF), which is common in older adults but hard to diagnose. Researchers tested a combination of five blood markers in 91 participants to see if they could distinguish HFpEF from other heart failure types. The goal is to make diagnosis easier and more accurate, leading to better care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

91 people

The number who actually took part.

Started

Jan 2022

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The inclusions will be done in the Cardiology department (Prof. F. Roubille) by the team of cardiologists trained in the study. Patients eligible for the study will be selected either from already hospitalized patients or from outside patients during the weekly consultation. In order to be representative of the population of interest (patients followed in cardiology consultation) and to limit inclusion bias, the inclusions will be exhaustive and consecutive. A collection of reasons for refusal will be made for the construction of the study flow chart.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria group 1 (ejection fraction ≥ 50%) : * Age \> or = 65, * heart failure (NT-proBNP ≥ 450 pg/mL during hospitalization or follow-up) * echocardiography showing an ejection fraction ≥ 50%, * patients already hospitalized and followed in cardiology consultation, * patients agreeing to sign informed consent, * patient affiliated to french health care system. Inclusion Criteria group 2 (ejection fraction \< 50%) : * Age \> or = 65, * heart failure (NT-proBNP ≥ 450 pg/mL during hospitalization or follow-up) * echocardiography showing an ejection fraction \< 50%, * patients already hospitalized and followed in cardiology consultation, * patients agreeing to sign informed consent, * patient affiliated to french health care system. Inclusion Criteria group 3 (without heart failure) : * Age \> or = 65, * patients already hospitalized and followed in cardiology consultation for one of the following pathology : stable coronaropathy without heart failure, arterial hypertension without heart failure, auricular fibrilation without heart failure * patients agreeing to sign informed consent, * patient affiliated to french health care system. Exclusion Criteria for all groups: * Hemodynamic instability (cardiogenic shock), * any condition leading to a prognosis of less than 7 days, * Known hepatocellular insufficiency, or known hepatic cirrhosis * ASAT / ALAT\> 10N excluding cardiac cause * Any conditions that may put the patient at risk or increase the risk of non-compliance with the protocol or lost to follow-up according to the opinion of the investigator * Patient under legal protection, under guardianship or under curatorship * Inability to give the subject informed information * Pregnant or breastfeeding woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diastolic heart failure heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

Contacts and locations

Locations

  • CHU Montpellier

    Montpellier, 34090, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.